Remiges Ventures Closes Second Fund With $95 Million; Launches RDiscovery Incubator
AsiaNet 88913
SEATTLE and TOKYO, April 9, 2021 /PRNewswire=KYODO JBN/ --
-- Remiges Ventures, a US-based cross-border venture capital firm with offices
in Seattle, WA and Tokyo, Japan, announced today the final closing of its
second fund, Remiges BioPharma Fund II raising a total of $95 million, and the
launch of RDiscovery, a new life sciences incubator to nurture and advance
early-stage therapeutic concepts and technologies.
Remiges Ventures, a US-based cross-border venture capital firm with offices in
Seattle, WA and Tokyo, Japan, announced today the final closing of its second
fund, Remiges BioPharma Fund II raising a total of $95 million by welcoming new
and returning investors, including Taiho Pharmaceutical Co., Ltd. (Tokyo,
Japan), 1Globe Capital, LLC (Boston, MA), EA Pharma Co., Ltd. (Tokyo, Japan)
and Senju Pharmaceutical Co., Ltd. (Osaka, Japan).
Remiges is also delighted to announce the launch of RDiscovery, a new life
sciences incubator to nurture and advance early-stage therapeutic concepts and
technologies with the goal of bringing them to a more mature stage of
development. RDiscovery will operate as a wholly owned subsidiary of Remiges
Ventures, allowing for an efficient and seamless transition of projects from
pre-seed, early development to a stage where company formation and investment
syndication makes sense. RDiscovery will serve as an integrated innovation
engine extending the capacity and capabilities of Remiges Ventures to execute
on its strategy of harnessing novel science from Japanese academia and
launching it on a patient-centered and commercially-focused path.
"We are extremely pleased to close our second fund with six major healthcare
companies both in the US and Japan and establish RDiscovery a new life science
incubator," commented Taro Inaba, Founder and Managing Partner of Remiges
Ventures. "The team is delighted to be working under our unique cross-border
strategy to build new companies based on innovative seed technologies invented
by researchers at Japanese academia and investing in early-stage companies
globally."
About Remiges Ventures
Remiges Ventures (
) focuses on company creation and investments in early-stage drug discovery and
development companies. With its team located in the US and Japan, Remiges
Ventures understands the drug discovery and biotech environments in both
regions and marries the entrepreneurship and biotech ecosystem in the US with
Japan's rich life science innovation. Additionally, with a limited partner base
that includes Japanese and US healthcare companies, Remiges Ventures possesses
a unique vantage point from which it creates and mines opportunities.
CONTACT:
Walter Olesiak
walter@remigesventures.com
SOURCE Remiges Ventures, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
